<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39346702</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1687-918X</ISSN><JournalIssue CitedMedium="Print"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>International journal of microbiology</Title><ISOAbbreviation>Int J Microbiol</ISOAbbreviation></Journal><ArticleTitle>Development and Evaluation of In-House ELISAs for the Detection of SARS-CoV-2-Specific Antibodies in COVID-19 Patients in Sri Lanka.</ArticleTitle><Pagination><StartPage>1331067</StartPage><MedlinePgn>1331067</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1331067</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2024/1331067</ELocationID><Abstract><AbstractText>COVID-19 serological tests complement the molecular diagnostics and can be used as important tool for serosurveillance and vaccine efficiency evaluation. The aim of this study was to develop and evaluate the diagnostic performance of an in-house ELISA for retrospective serosurveillance of SARS-CoV-2. Total IgG and IgM levels in sera of PCR positive SARS-CoV-2 patients (<i>n</i> = 50) from North Colombo Teaching Hospital were evaluated and compared with sera (<i>n</i> = 50) collected from prepandemic healthy individuals as controls. Patient sample collection was initiated before vaccination programme was widely started within the country. Seropositivity of 94.0% (<i>n</i> = 47/50) was observed for either IgG or IgM anti-SARS-CoV-2 antibodies against receptor binding domain of spike protein or nucleocapsid protein in confirmed cases while none of controls were seropositive. In contrast, the seropositivity of only 48.0% (<i>n</i> = 24/50) was demonstrated with commercial ELISA kits for detection of IgG or IgM. All samples detected seropositive by commercially available kits remained seropositive with either in-house IgM or IgG ELISA. Significant correlations (<i>p</i> ≤ 0.001) were observed between Ab levels and day of sampling from the onset of illness. The overall sensitivity values of the in-house assays were 66.7%, 96.9%, and 100.0% for the first, second, and third week or longer after onset of symptoms for either in-house IgM or IgG ELISAs. Majority of the patients (&gt;80.0%) were seropositive, regardless of age (&lt;60 vs. &gt;60 years), gender (male vs. female), or clinical severity (mild vs. moderate/severe). These data suggest that the developed in-house ELISAs can be applied to assess anti-SARS-CoV-2 antibody levels induced by either natural infections or vaccination.</AbstractText><CopyrightInformation>Copyright © 2024 Sisira L. Pathirana et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pathirana</LastName><ForeName>Sisira L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deepachandi</LastName><ForeName>Bhagya</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7601-4845</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Life Sciences Faculty of Science, NSBM Green University, Mahenwaththa, Pitipana, Homagama, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunasekara</LastName><ForeName>Peshala</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7017-520X</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernando</LastName><ForeName>Narmada</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Inoka C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Zoology and Environment Sciences Faculty of Science University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangani</LastName><ForeName>Dakshika</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thambyarajah</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dasanayake</LastName><ForeName>Dhanushka</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology Medical Research Institute, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rajiva</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Immunology Medical Research Institute, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premawansa</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Zoology and Environment Sciences Faculty of Science University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitsche</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Biological Threats and Special Pathogens Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handunnetti</LastName><ForeName>Shiroma M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry Molecular Biology and Biotechnology University of Colombo, Colombo, Sri Lanka.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>Int J Microbiol</MedlineTA><NlmUniqueID>101516125</NlmUniqueID></MedlineJournalInfo><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346702</ArticleId><ArticleId IdType="pmc">PMC11427722</ArticleId><ArticleId IdType="doi">10.1155/2024/1331067</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Sabato L., Vaccari G., Lelli D., Lavazza A., Castrucci M. R., Moreno A. A48 identification and full-genome characterization of alpha- and beta-coronaviruses viruses from bats in Italy. Virus Evolution . 2019;5(1) doi: 10.1093/ve/vez002.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/vez002.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Liu L., Kou G., et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. Journal of Clinical Microbiology . 2020;58(6) doi: 10.1128/JCM.00461-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00461-20</ArticleId><ArticleId IdType="pmc">PMC7269413</ArticleId><ArticleId IdType="pubmed">32229605</ArticleId></ArticleIdList></Reference><Reference><Citation>Algaissi A., Alfaleh M. A., Hala S., et al. SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. Scientific Reports . 2020;10(1) doi: 10.1038/s41598-020-73491-5.16561</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73491-5</ArticleId><ArticleId IdType="pmc">PMC7538990</ArticleId><ArticleId IdType="pubmed">33024213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) BioScience Trends . 2020;14(1):69–71. doi: 10.5582/bst.2020.01020.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2020.01020</ArticleId><ArticleId IdType="pubmed">31996494</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldometer.  
 https://www.worldometers.info/coronavirus/
</Citation></Reference><Reference><Citation>Lauer S. A., Grantz K. H., Bi Q., et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine . 2020;172(9):577–582. doi: 10.7326/M20-0504.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-0504</ArticleId><ArticleId IdType="pmc">PMC7081172</ArticleId><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X.-W., Wu X.-X., Jiang X.-G., et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ . 2020;368 doi: 10.1136/bmj.m606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m606</ArticleId><ArticleId IdType="pmc">PMC7224340</ArticleId><ArticleId IdType="pubmed">32075786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Gao Q., Wang T., et al. Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19) medRxiv . 2020 doi: 10.1101/2020.03.17.20036954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.17.20036954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayouba A., Thaurignac G., Morquin D., et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV-2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. Journal of Clinical Virology . 2020;129 doi: 10.1016/j.jcv.2020.104521.104521</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104521</ArticleId><ArticleId IdType="pmc">PMC7308014</ArticleId><ArticleId IdType="pubmed">32623350</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlton C. L., Kanji J. N., Johal K., et al. Evaluation of six commercial mid- to high-volume antibody and six point-of-care lateral flow assays for detection of SARS-CoV-2 antibodies. Journal of Clinical Microbiology . 2020;58(10) doi: 10.1128/JCM.01361-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01361-20</ArticleId><ArticleId IdType="pmc">PMC7512179</ArticleId><ArticleId IdType="pubmed">32665420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones S., Carley S., Harrison M. An introduction to power and sample size estimation. Emergency Medicine Journal . 2003;20(5):453–458. doi: 10.1136/emj.20.5.453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emj.20.5.453</ArticleId><ArticleId IdType="pmc">PMC1726174</ArticleId><ArticleId IdType="pubmed">12954688</ArticleId></ArticleIdList></Reference><Reference><Citation>Herroelen P. H., Martens G. A., Smet D. D., Swaerts K., Decavele A. Humoral immune response to SARS-CoV-2: comparative clinical performance of seven commercial serology tests. American Journal of Clinical Pathology . 2020;154(5):610–619. doi: 10.1093/ajcp/aqaa140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa140</ArticleId><ArticleId IdType="pmc">PMC7454302</ArticleId><ArticleId IdType="pubmed">32808976</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeewandara C., Guruge D., Abyrathna I. S., et al. Seroprevalence of SARS-CoV-2 infection in the Colombo municipality region, Sri Lanka. Frontiers in Public Health . 2021;9 doi: 10.3389/fpubh.2021.724398.724398</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.724398</ArticleId><ArticleId IdType="pmc">PMC8632812</ArticleId><ArticleId IdType="pubmed">34869146</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakumara P. D., Jeewandara C., Bary F., et al. Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals. medRxiv . 2023 doi: 10.1101/2023.01.05.23284247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.05.23284247</ArticleId><ArticleId IdType="pmc">PMC10876109</ArticleId><ArticleId IdType="pubmed">37313783</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther J. R. The ELISA Guidebook . 2nd. New York, NY, USA: Springer Science+Business Media; 2009.</Citation></Reference><Reference><Citation>Deepachandi B., Weerasinghe S., Ranasinghe S., et al. First serological study revealing high humoral response and evidence for antigenic heterogeneity in Leishmania donovani induced CL in Sri Lanka. BioMed Research International . 2020;2020:1–11. doi: 10.1155/2020/5271657.5271657</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5271657</ArticleId><ArticleId IdType="pmc">PMC7599090</ArticleId><ArticleId IdType="pubmed">33145352</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield E. A., editor. Antibodies-a Laboratory Manual . 2nd. Cold Spring Harbor, NY, USA: Cold Spring Harbor Laboratory Press; 2014.</Citation></Reference><Reference><Citation>Bio News. Quarterly e-newsletter of the Institute of Biology, Sri Lanka. Biology News . 2022;2(4):11–13.</Citation></Reference><Reference><Citation>Adams E., Ainsworth M., Anand R., et al. Antibody testing for COVID-19: a report from the national covid scientific advisory panel. Wellcome Open Research . 2020;5:p. 139. doi: 10.12688/wellcomeopenres.15927.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15927.1</ArticleId><ArticleId IdType="pmc">PMC7941096</ArticleId><ArticleId IdType="pubmed">33748431</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayathilaka D., Jeewandara C., Gomes L., et al. Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. Clinical and Experimental Immunology . 2022;208(3):323–331. doi: 10.1093/cei/uxac009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cei/uxac009</ArticleId><ArticleId IdType="pmc">PMC8807318</ArticleId><ArticleId IdType="pubmed">35641142</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrey D. O., Cohen P., Meyer B., et al. Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. European Journal of Clinical Investigation . 2020;50(10) doi: 10.1111/eci.13357.e13357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13357</ArticleId><ArticleId IdType="pmc">PMC7404380</ArticleId><ArticleId IdType="pubmed">32691863</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombini A., Vigano M., Tomaiuolo R., et al. Exploratory assessment of serological tests to determine antibody titer against SARS-CoV-2: appropriateness and limits. Journal of Clinical Laboratory Analysis . 2022;36(5) doi: 10.1002/jcla.24363.e24363</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.24363</ArticleId><ArticleId IdType="pmc">PMC9102736</ArticleId><ArticleId IdType="pubmed">35334493</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Liu W., Zheng Y., et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. Microbes and Infection . 2020;22(4-5):206–211. doi: 10.1016/j.micinf.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233230</ArticleId><ArticleId IdType="pubmed">32425648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan C. W., Parker K., Tesic V., et al. Analytical and clinical evaluation of the automated elecsys anti-SARS-CoV-2 antibody assay on the Roche cobas e602 analyzer. American Journal of Clinical Pathology . 2022;157(1):109–118. doi: 10.1093/ajcp/aqab092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqab092</ArticleId><ArticleId IdType="pmc">PMC7454296</ArticleId><ArticleId IdType="pubmed">32814955</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marinis Y., Sunnerhagen T., Bompada P., et al. Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test. Infection Ecology and Epidemiology . 2020;10 doi: 10.1080/20008686.2020.1821513.1821513</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20008686.2020.1821513</ArticleId><ArticleId IdType="pmc">PMC7534290</ArticleId><ArticleId IdType="pubmed">33062217</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.-X., Liu B.-Z., Deng H.-J., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine . 2020;26(6):845–848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Wang M., Zuo Z., et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. International Journal of Infectious Diseases . 2020;94:49–52. doi: 10.1016/j.ijid.2020.03.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.065</ArticleId><ArticleId IdType="pmc">PMC7194885</ArticleId><ArticleId IdType="pubmed">32251798</ArticleId></ArticleIdList></Reference><Reference><Citation>Turbett S. E., Anahtar M., Dighe A. S., et al. Evaluation of three commercial SARS-CoV-2 serologic assays and their performance in two-test algorithms. Journal of Clinical Microbiology . 2020;59(1) doi: 10.1128/JCM.01892-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01892-20</ArticleId><ArticleId IdType="pmc">PMC7771444</ArticleId><ArticleId IdType="pubmed">33020186</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo A. C. L. M., Prestes G. d S., Colonetti T., et al. A systematic review and meta-analysis of the accuracy of SARS-CoV-2 IgM and IgG tests in individuals with COVID-19. Journal of Clinical Virology . 2022;148 doi: 10.1016/j.jcv.2022.105121.105121</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105121</ArticleId><ArticleId IdType="pmc">PMC8863416</ArticleId><ArticleId IdType="pubmed">35245882</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman B., Lester S., Mills L., et al. Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and sero-surveillance. bioRxiv . 2020 doi: 10.1101/2020.04.24.057323.057323</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.24.057323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Ren L., Yang S., et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Clinical Infectious Diseases . 2020;71(15):778–785. doi: 10.1093/cid/ciaa310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa310</ArticleId><ArticleId IdType="pmc">PMC7184472</ArticleId><ArticleId IdType="pubmed">32198501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>